LGM
LUMO

Logos Global Management’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Logos Global Management’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-50,000
Closed -$825K – 61
2020
Q2 		$825K Buy
+50,000
New +$595K 0.16% 43

Other funds holding LUMO

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Logos Global Management's LUMO Position: Q3 2020 in Review

Logos Global Management sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2020, closing a stake of 50,000 shares — an estimated $825K sold.

Logos Global Management first reported a position in LUMO in Q2 2020 and held it in 1 quarter. The position peaked at $825K in Q2 2020. 38 funds tracked by Wall St. Rank hold LUMO as of Q3 2020.

  • Logos Global Management reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Logos Global Management sold 50,000 Lumos Pharma, Inc. Common Stock shares in Q3 2020, an estimated $825K.
  • Logos Global Management first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Logos Global Management's Lumos Pharma, Inc. Common Stock position peaked at $825K in Q2 2020.
  • 38 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2020.

Based on Logos Global Management's 13F filing for Q3 2020, filed 16 Nov 2020.